カテゴリ： Allied Market Research, 世界, 医療/バイオ

ベータラクタム及びベータラクタマーゼ阻害剤の世界市場：薬物クラス別、疾患別、投与経路別

◆英語タイトル：Beta-lactam and Beta-lactamase Inhibitors Market by Drug Class (Penicillin, Cephalosporin, Carbapenem, Monobactam, and Combination), Disease (Urinary Tract Infection, Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Blood Stream Infection, and Other Diseases), and Route of Administration (Oral, Intravenous, and Other Route of Administrations): Global Opportunity Analysis and Industry Forecast, 2019–2028
◆商品コード：AMR9NV046
◆発行会社（リサーチ会社）：Allied Market Research
◆発行日：2019年8月
◆ページ数：309
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆販売価格オプション（消費税別）
Single UserUSD5,370 ⇒換算￥558,480見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算￥670,800見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算￥935,480見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
※Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。
当調査レポートでは、ベータラクタム及びベータラクタマーゼ阻害剤の世界市場について調査・分析し、市場概要、薬物クラス別（ペニシリン、セファロスポリン、カルバペネム、モノバクタム、組み合わせ）分析、疾患別（尿路感染症、呼吸器感染症、皮膚感染症、合併症のある尿路感染症（cUTI）、合併症のある腹腔内感染症（cIAI）、院内肺炎、血流感染症、その他の疾患）分析、投与経路別（経口、静脈内、その他の投与経路）分析、地域別分析、企業動向など含め、以下の構成でお届け致します。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・ベータラクタム及びベータラクタマーゼ阻害剤の世界市場：薬物クラス別（ペニシリン、セファロスポリン、カルバペネム、モノバクタム、組み合わせ）
・ベータラクタム及びベータラクタマーゼ阻害剤の世界市場：疾患別（尿路感染症、呼吸器感染症、皮膚感染症、合併症のある尿路感染症（cUTI）、合併症のある腹腔内感染症（cIAI）、院内肺炎、血流感染症、その他の疾患）
・ベータラクタム及びベータラクタマーゼ阻害剤の世界市場：投与経路別（経口、静脈内、その他の投与経路）
・ベータラクタム及びベータラクタマーゼ阻害剤の世界市場：地域別
・企業動向

【レポートの概要】

The global beta-lactam and beta-lactamase inhibitors market size was $27,126 million in 2018, and is projected to reach $34,170 million by 2028, growing at a CAGR of 2.3% from 2019 to 2028.

Beta-lactam and beta-lactamase inhibitors is a most important type of antibacterial agent used for fighting bacterial infections. In addition, these are used to kill or prevent the growth of microorganisms. Based on the molecular structure, beta-lactam and beta-lactamase inhibitors are drug classified into penicillin, cephalosporin, carbapenem, monobactam, and combination.

There is an increase in the demand for beta-lactam and beta-lactamase inhibitors, owing to increased consumption in low- and middle-income countries (LMICs) and rise in prevalence of infectious diseases. In addition, development of novel approaches for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections and a large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of beta-lactam and beta-lactamase inhibitors and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.

The global beta-lactam and beta-lactamase inhibitors market is segmented based on drug class, disease, route of administration, and region. Based on the drug class, the market is classified into penicillin, cephalosporin, carbapenem, monobactam, and combination. Combination segment is further categorized into penicillin/beta lactamase inhibitors, cephalosporins/beta lactamase inhibitors, and carbapenems/beta lactamase inhibitors. Depending on the disease segment, the market is divided into urinary tract infection (excluding cUTI), respiratory infection, skin infection, complicated urinary tract infection (cUTI), complicated intra-abdominal infections (cIAI), nosocomial pneumonia, blood stream infection, and other diseases. Nosocomial pneumonia segment is further divided into hospital acquired pneumonia, ventilator associated pneumonia, and other nosocomial pneumonia. Based on route of administration, the market is classified into oral, intravenous, and others. Based on region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
 This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2028, which assists to identify the prevailing market opportunities.
 An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
 A comprehensive analysis of the factors that drive and restrain the growth of the global beta-lactam and beta-lactamase inhibitors market is provided.
 An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS
• By Drug Class
o Penicillin
o Cephalosporin
o Carbapenem
o Monobactam
o Combination
 Penicillin/Beta Lactamase Inhibitors
 Cephalosporins/Beta Lactamase Inhibitors
 Carbapenems/Beta Lactamase Inhibitors
• By Disease
o Urinary Tract Infection (excluding cUTI)
o Respiratory Infection
o Skin Infection
o Complicated Urinary Tract Infection (cUTI)
o Complicated Intra-Abdominal Infections (cIAI)
o Nosocomial Pneumonia
 Hospital Acquired Pneumonia
 Ventilator Associated Pneumonia
 Other Nosocomial Pneumonia
o Blood Stream Infection
o Other Diseases
• By Route of Administration
o Oral
o Intravenous
o Others
• By Region
o North America
 U.S.
 Canada
 Mexico
o Europe
 Germany
 France
 Spain
 Italy
 UK
 Rest of Europe
o Asia-Pacific
 Japan
 India
 China
 South Korea
 Thailand
 Taiwan
 Vietnam
 Rest of Asia-Pacific
o LAMEA
 Brazil
 Saudi Arabia
 South Africa
 Rest of LAMEA

KEY MARKET PLAYERS
• Abbott Laboratories
• Allergan Plc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Merck & Co. Inc.
• Mylan N.V.
• Novartis International AG (Sandoz)
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.

The other players in the value chain (profiles not included in the report)
• Hikma Pharmaceuticals
• Melinta Therapeutics
• Eli Lilly and Company
• Shionogi, Inc.
• AstraZeneca plc

【レポートの目次】

Chapter 1: Introduction

1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments

1.3.1. List of Key Players Profiled In The Report

1.4. Research Methodology

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1.1. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope
3.2. Key Findings

3.2.1. Top Investment Pockets

3.3. Top Winning Strategies

3.3.1. Top Player Positioning, 2018

3.4. Porter’S Five Forces Analysis
3.5. Market Dynamics

3.5.1. Drivers

3.5.1.1. Increased Consumption In Low And Middle-Income Countries (Lmics)
3.5.1.2. Rise In Prevalence of Infectious Diseases
3.5.1.3. Development of Novel Approaches For New Beta-Lactam And Beta-Lactamase Inhibitors For Treating Bacterial Infections

3.5.2. Restraints

3.5.2.1. Development of Beta-Lactam Resistance
3.5.2.2. Longer Approval Time By The Regulatory Bodies

3.5.3. Opportunity

3.5.3.1. Discovery of Advanced Prospect Molecules And Novel Combination Therapies To Treat Antibiotic-Resistant Microbial Infections

3.6. Antimicrobial Resistance And Countermeasure Trends

3.6.1. Countermeasure Trends

Chapter 4: Beta-Lactam And Beta Lactamase Inhibitors Market, By Drug Class

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Penicillin

4.2.1. Key Market Trends And Growth Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country

4.3. Cephalosporin

4.3.1. Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country

4.4. Carbapenem

4.4.1. Key Market Trends And Growth Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis, By Country

4.5. Monobactam

4.5.1. Key Market Trends And Growth Opportunities
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis, By Country

4.6. Combination

4.6.1. Key Market Trends And Growth Opportunities
4.6.2. Market Size And Forecast, By Type

4.6.2.1. Penicillin/Beta Lactamase Inhibitors

4.6.2.1.1. Market Size And Forecast

4.6.2.2. Cephalosporins/Beta Lactamase Inhibitors

4.6.2.2.1. Market Size And Forecast

4.6.2.3. Carbapenems/Beta Lactamase Inhibitors

4.6.2.3.1. Market Size And Forecast

4.6.3. Market Size And Forecast, By Region
4.6.4. Market Analysis, By Country

Chapter 5: Beta-Lactam And Beta Lactamase Inhibitors Market, By Disease

5.1. Overview

5.1.1. Market Size And Forecast

5.2. Urinary Tract Infection (Excluding Cuti)

5.2.1. Market Size And Forecast, By Region
5.2.2. Market Analysis, By Country

5.3. Respiratory Infection

5.3.1. Market Size And Forecast, By Region
5.3.2. Market Analysis, By Country

5.4. Skin Infection

5.4.1. Market Size And Forecast, By Region
5.4.2. Market Analysis, By Country

5.5. Complicated Urinary Tract Infection (Cuti)

5.5.1. Market Size And Forecast, By Region
5.5.2. Market Analysis, By Country
5.5.3. Number of Patients, By Country

5.6. Complicated Intra-Abdominal Infections (Ciai)

5.6.1. Market Size And Forecast, By Region
5.6.2. Market Analysis, By Country
5.6.3. Number of Patients, By Country

5.7. Nosocomial Pneumonia

5.7.1. Market Size And Forecast, By Type

5.7.1.1. Hospital Acquired Pneumonia

5.7.1.1.1. Market Size And Forecast

5.7.1.2. Ventilator Associated Pneumonia

5.7.1.2.1. Market Size And Forecast

5.7.1.3. Other Nosocomial Pneumonia

5.7.1.3.1. Market Size And Forecast

5.7.2. Market Size And Forecast, By Region
5.7.3. Market Analysis, By Country
5.7.4. Number of Patients, By Country

5.8. Blood Stream Infection

5.8.1. Market Size And Forecast, By Region
5.8.2. Market Analysis, By Country
5.8.3. Number of Patients, By Country

5.9. Other Diseases

5.9.1. Market Size And Forecast, By Region
5.9.2. Market Analysis, By Country

Chapter 6: Beta-Lactam And Beta Lactamase Inhibitors Market, By Route of Administration

6.1. Overview

6.1.1. Market Size And Forecast

6.2. Oral

6.2.1. Market Size And Forecast, By Region
6.2.2. Market Analysis, By Country

6.3. Intravenous

6.3.1. Market Size And Forecast, By Region
6.3.2. Market Analysis, By Country

6.4. Others

6.4.1. Market Size And Forecast, By Region
6.4.2. Market Analysis, By Country

Chapter 7: Beta-Lactam And Beta-Lactamase Inhibitors Market, By Region

7.1. Overview

7.1.1. Market Size And Forecast

7.2. North America

7.2.1. Key Market Trends And Opportunities
7.2.2. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country

7.2.2.1. U.S. Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.2.2.2. U.S. Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.2.2.3. U.S. Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.2.2.4. Canada Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.2.2.5. Canada Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.2.2.6. Canada Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.2.2.7. Mexico Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.2.2.8. Mexico Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.2.2.9. Mexico Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration

7.2.3. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class
7.2.4. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease
7.2.5. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration

7.3. Europe

7.3.1. Key Market Trends And Opportunities
7.3.2. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country

7.3.2.1. Germany Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.2. Germany Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.3. Germany Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.4. France Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.5. France Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.6. France Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.7. Spain Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.8. Spain Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.9. Spain Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.10. Italy Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.11. Italy Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.12. Italy Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.13. Uk Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.14. Uk Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.15. Uk Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.16. Rest of Europe Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.17. Rest of Europe Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.18. Rest of Europe Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration

7.3.3. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class
7.3.4. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease
7.3.5. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration

7.4. Asia-Pacific

7.4.1. Key Market Trends And Opportunities
7.4.2. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country

7.4.2.1. Japan Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.2. Japan Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.3. Japan Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.4. India Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.5. India Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.6. India Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.7. China Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.8. China Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.9. China Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.10. South Korea Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.11. South Korea Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.12. South Korea Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.13. Indonesia Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.14. Indonesia Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.15. Indonesia Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.16. Thailand Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.17. Thailand Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.18. Thailand Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.19. Vietnam Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.20. Vietnam Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.21. Vietnam Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.22. Taiwan Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.23. Taiwan Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.24. Taiwan Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.25. Rest of Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.26. Rest of Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.27. Rest of Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration

7.4.3. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class
7.4.4. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease
7.4.5. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration

7.5. Lamea

7.5.1. Key Market Trends And Opportunities
7.5.2. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country

7.5.2.1. Brazil Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.5.2.2. Brazil Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.5.2.3. Brazil Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.5.2.4. Saudi Arabia Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.5.2.5. Saudi Arabia Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.5.2.6. Saudi Arabia Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.5.2.7. South Africa Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.5.2.8. South Africa Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.5.2.9. South Africa Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.5.2.10. Rest of Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.5.2.11. Rest of Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.5.2.12. Rest of Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration

7.5.3. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class
7.5.4. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease
7.5.5. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration

Chapter 8: Company Profiles

8.1. Abbott Laboratories

8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance

8.2. Allergan Plc.

8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.2.6. Key Strategic Moves And Developments

8.3. F. Hoffmann-La Roche Ltd.

8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance

8.4. Glaxosmithkline Plc

8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance

8.5. Merck & Co. Inc.

8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves And Developments

8.6. Mylan N.V.

8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.6.6. Key Strategic Moves And Developments

8.7. Novartis International Ag (Sandoz)

8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance

8.8. Pfizer Inc.

8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.8.6. Key Strategic Moves And Developments

8.9. Sanofi

8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance

8.10. Teva Pharmaceutical Industries Ltd.

8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance

List of Tables

Table 01. Classification of Beta-Lactamase Inhibitors And Its Properties
Table 02. Global Beta-Lactam And Beta Lactamase Inhibitors Market, By Drug Class, 2018–2028 ($Million)
Table 03. Beta-Lactam And Beta Lactamase Inhibitors Market For Penicillin, By Region, 2018–2028 ($Million)
Table 04. Beta-Lactam And Beta Lactamase Inhibitors Market For Cephalosporin, By Region, 2018–2028 ($Million)
Table 05. Beta-Lactam And Beta Lactamase Inhibitors Market For Carbapenem, By Region, 2018–2028 ($Million)
Table 06. Beta-Lactam And Beta Lactamase Inhibitors Market For Monobactam, By Region, 2018–2028 ($Million)
Table 07. Beta-Lactam And Beta Lactamase Inhibitors Market For Combination, By Type, 2018–2028 ($Million)
Table 08. Beta-Lactam And Beta Lactamase Inhibitors Market For Combination, By Region, 2018–2028 ($Million)
Table 09. Global Beta-Lactam And Beta Lactamase Inhibitors Market, By Disease, 2018–2028 ($Million)
Table 10. Beta-Lactam And Beta Lactamase Inhibitors Market For Urinary Tract Infection (Excluding Cuti), By Region, 2018–2028 ($Million)
Table 11. Beta-Lactam And Beta Lactamase Inhibitors Market For Respiratory Infection, By Region, 2018–2028 ($Million)
Table 12. Beta-Lactam And Beta Lactamase Inhibitors Market For Skin Infection, By Region, 2018–2028 ($Million)
Table 13. Beta-Lactam And Beta Lactamase Inhibitors Market For Complicated Urinary Tract Infection (Cuti), By Region, 2018–2028 ($Million)
Table 14. Number of Patients For Complicated Urinary Tract Infection (Cuti), By Country, 2018–2028 (Thousands)
Table 15. Beta-Lactam And Beta Lactamase Inhibitors Market For Complicated Intra-Abdominal Infections (Ciai), By Region, 2018–2028 ($Million)
Table 16. Number of Patients For Complicated Intra-Abdominal Infections (Ciai), By Country, 2018–2028 (Thousands)
Table 17. Beta Lactam & Beta Lactamase Inhibitors Market For Nosocomial Pneumonia, By Type, 2018–2028 ($Million)
Table 18. Beta-Lactam And Beta Lactamase Inhibitors Market For Nosocomial Pneumonia, By Region, 2018–2028 ($Million)
Table 19. Number of Patients For Nosocomial Pneumonia, By Country, 2018–2028 (Thousands)
Table 20. Beta-Lactam And Beta Lactamase Inhibitors Market For Blood Stream Infection, By Region, 2018–2028 ($Million)
Table 21. Number of Patients For Blood Stream Infection, By Country, 2018–2028 (Thousands)
Table 22. Beta-Lactam And Beta Lactamase Inhibitors Market For Other Diseases, By Region, 2018–2028 ($Million)
Table 23. Global Beta-Lactam And Beta Lactamase Inhibitors Market, By Route of Administration, 2018–2028 ($Million)
Table 24. Beta-Lactam And Beta Lactamase Inhibitors Market For Oral, By Region, 2018–2028 ($Million)
Table 25. Beta-Lactam And Beta Lactamase Inhibitors Market For Intravenous, By Region, 2018–2028 ($Million)
Table 26. Beta-Lactam And Beta Lactamase Inhibitors Market For Others, By Region, 2018–2028 ($Million)
Table 27. Global Beta-Lactam And Beta-Lactamase Inhibitors Market Revenue, By Region, 2018–2028 ($Million)
Table 28. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country, 2018-2028 ($Million)
Table 29. U.S. Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 30. U.S. Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 31. U.S. Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 32. Canada Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 33. Canada Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 34. Canada Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 35. Mexico Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 36. Mexico Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 37. Mexico Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 38. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 39. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 40. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 41. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country, 2018-2028 ($Million)
Table 42. Germany Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 43. Germany Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 44. Germany Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 45. France Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 46. France Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 47. France Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 48. Spain Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 49. Spain Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 50. Spain Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 51. Italy Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 52. Italy Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 53. Italy Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 54. Uk Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 55. Uk Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 56. Uk Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 57. Rest of Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 58. Rest of Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 59. Rest of Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 60. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 61. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 62. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 63. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country, 2018-2028 ($Million)
Table 64. Japan Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 65. Japan Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 66. Japan Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 67. India Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 68. India Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 69. India Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 70. China Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 71. China Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 72. China Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 73. South Korea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 74. South Korea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 75. South Korea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 76. Indonesia Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 77. Indonesia Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 78. Indonesia Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 79. Thailand Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 80. Thailand Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 81. Thailand Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 82. Vietnam Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 83. Vietnam Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 84. Vietnam Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 85. Taiwan Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 86. Taiwan Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 87. Taiwan Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 88. Rest of Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 89. Rest of Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 90. Rest of Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 91. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 92. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 93. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 94. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country, 2018-2028 ($Million)
Table 95. Brazil Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 96. Brazil Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 97. Brazil Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 98. Saudi Arabia Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 99. Saudi Arabia Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 100. Saudi Arabia Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 101. South Africa Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 102. South Africa Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 103. South Africa Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 104. Rest of Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 105. Rest of Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 106. Rest of Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 107. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class, 2018-2028 ($Million)
Table 108. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease, 2018-2028 ($Million)
Table 109. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration, 2018-2028 ($Million)
Table 110. Abbott: Company Snapshot
Table 111. Abbott: Operating Segments
Table 112. Abbott: Product Portfolio
Table 113. Allergan: Company Snapshot
Table 114. Allergan: Operating Segments
Table 115. Allergan: Product Portfolio
Table 116. Roche: Company Snapshot
Table 117. Roche: Operating Segments
Table 118. Roche: Product Portfolio
Table 119. Gsk: Company Snapshot
Table 120. Gsk: Operating Segments
Table 121. Gsk: Product Portfolio
Table 122. Merck: Company Snapshot
Table 123. Merck: Operating Segments
Table 124. Merck: Product Portfolio
Table 125. Mylan: Company Snapshot
Table 126. Mylan: Operating Segments
Table 127. Mylan: Product Portfolio
Table 128. Novartis Ag: Company Snapshot
Table 129. Novartis: Operating Segments
Table 130. Novartis Ag: Product Portfolio
Table 131. Pfizer: Company Snapshot
Table 132. Pfizer: Operating Segments
Table 133. Pfizer: Product Portfolio
Table 134. Sanofi: Company Snapshot
Table 135. Sanofi: Operating Segments
Table 136. Sanofi: Product Portfolio
Table 137. Teva: Company Snapshot
Table 138. Teva: Operating Segments
Table 139. Teva: Product Portfolio

【レポートのキーワード】

ベータラクタム及びベータラクタマーゼ阻害剤、ペニシリン、セファロスポリン、カルバペネム、モノバクタム、組み合わせ、尿路感染症、呼吸器感染症、皮膚感染症、合併症のある尿路感染症（cUTI）、合併症のある腹腔内感染症（cIAI）、院内肺炎、血流感染症、経口、静脈内

【免責事項】
https://www.marketreport.jp/reports-disclaimer
★医療情報レポート[ベータラクタム及びベータラクタマーゼ阻害剤の世界市場：薬物クラス別、疾患別、投与経路別]についてメールでお問い合わせはこちら

※関連の医療情報レポート

  1. インフルエンザワクチンの世界市場：ワクチンタイプ別（四価、三価）、タイプ別（季節性、パンデミック）、技術別（卵ベース、細胞ベース）、年齢別（小児、成人）、投与経路別（注射、点鼻薬）
    AMR9DC028 / Allied Market Research / 2019年10月 / 当調査レポートでは、インフルエンザワクチンの世界市場について調査・分析し、イントロダクション、エグゼクティブサマリ－、市場概要、ワクチンタイプ別分析、技術別分析、年齢別分析、投与経路別分析、地域別分析、企業概要などを含め以下の構成でお届けします。 ・イントロダクション ・エグゼクティブサマリ－ ・市場概要 ・インフルエンザワクチンの世界市場：ワクチンタイプ別（四価、三価） ・インフルエンザワクチンの世界市場：技術別（卵ベース、細胞ベース） ・インフルエンザワクチンの世界市場：年齢別（小児、成人） ・インフルエンザワクチンの世界市場：投与経路別（注射、点鼻薬） ・インフルエンザワクチンの世界市場：地域別 ・企業概要...The global influenza vaccine market was valued at $3.96 billion in 2018, and is projected to reach $6.20 billion by 2026, registering a CAGR of 5.9% from 2019 to 2026. Influenza, commonly known as flu, is a contagious respiratory infection caused by influenza viruses. Four types of influenza viruses include type A, B, C, and D. The most common types of influenza viruses responsible for seasonal flu each year are type A and B. These viruses enter into the respiratory system of an individual, and are transmitted to other individuals by direct contact or inhalation of virus-laden aerosols. The ideal...
  2. 制酸薬の世界市場：薬物クラス別（プロトンポンプ阻害剤、H2拮抗薬、酸中和剤）、製剤別（錠剤、液体、粉末）、地域別予測
    BZW9OT005 / Bizwit Research & Consulting / 2019年9月 / 本資料は、制酸薬の世界市場について調べ、制酸薬の世界規模、市場動向、市場環境、薬物クラス別（プロトンポンプ阻害剤、H2拮抗薬、酸中和剤）分析、製剤別（錠剤、液体、粉末）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・制酸薬の世界市場概要 ・制酸薬の世界市場環境 ・制酸薬の世界市場動向 ・制酸薬の世界市場規模 ・制酸薬の世界市場規模：薬物クラス別（プロトンポンプ阻害剤、H2拮抗薬、酸中和剤） ・制酸薬の世界市場規模：製剤別（錠剤、液体、粉末） ・制酸薬の世界市場：地域別市場規模・分析...Antacid Market is valued approximately USD 6.13 billion in 2018 and is anticipated to grow with a healthy growth rate of more than 3.9% over the forecast period 2019-2026. The growingincrease prevalence of gastric diseases has led the healthcare and pharmaceuticals providers towards the development of more enhanced gastric solution to get relief from acidity and heartburns. Antacids are the class of drugs thatwhich reduces gastric acidity resulting in the increase pH of the stomach and duodenum. The growing prevalence of gastric diseases among geriatric population has led to the increase in demand for antacids. The advancement of e-commerce industry...
  3. 癌補助療法薬剤の世界市場：薬物クラス別
    GV9NV136 / Grand View Research / 2019年6月 / 当調査レポートでは、癌補助療法薬剤の世界市場について調査・分析し、市場動向、薬物クラス別（G-CSF、エリスロポエチン刺激剤（ESA）、制吐剤、ビスホスホネート、オピオイド、NSAIDおよびその他）分析、地域別分析、競合分析などを含め次の構成でお届け致します。 ・調査手法及び範囲 ・エグゼクティブサマリー ・市場動向 ・癌補助療法薬剤の世界市場：薬物クラス別（G-CSF、エリスロポエチン刺激剤（ESA）、制吐剤、ビスホスホネート、オピオイド、NSAIDおよびその他） ・癌補助療法薬剤の世界市場：地域別 ・競合分析 ...The global cancer supportive care drugs market size is projected to reach USD 22.9 billion by 2026, as per a new report by Grand View Research, Inc. It is expected to progress at a CAGR of 1.0% over the forecast period. Supportive care in cancer focuses on prevention and management of symptoms and side-effects associated with cancer and its treatment. Key side effects caused by cancer treatment include anemia, neutropenia, nausea and vomiting, pain, and bone metastasis. Rise in the number of people suffering from the effects of anti-cancer therapies will drive the market, globally. The higher efficacy of supportive...
  4. 嚢胞性線維症の治療薬の世界市場：クラス別（膵臓酵素サプリメント、粘液溶解薬、気管支拡張薬、CFTR調整剤）、投与経路別（経口薬、吸入薬）、地域別予測
    BZW8D79 / Bizwit Research & Consulting / 2018年11月 / 本資料は、嚢胞性線維症の治療薬の世界市場について調べ、嚢胞性線維症の治療薬の世界規模、市場動向、市場環境、クラス別（膵臓酵素サプリメント、粘液溶解薬、気管支拡張薬、CFTR調整剤）分析、投与経路別（経口薬、吸入薬）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。業界の主要なプレイヤーはAbbvie、F. Hoffmann-La Roche Ltd.、Gilead、Vertex Pharmaceuticals Inc.、Alaxiaなどです。 ・イントロダクション ・エグゼクティブサマリー ・嚢胞性線維症の治療薬の世界市場概要 ・嚢胞性線維症の治療薬の世界市場環境...Global Cystic Fibrosis Therapeutics Market to reach USD XX billion by 2025. Global Cystic Fibrosis Therapeutics Market valued approximately USD XX billion in 2017 is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2018-2025. The major driving factor of global cystic fibrosis therapeutics market are rising prevalence of cystic fibrosis, rising awareness about cystic fibrosis therapy, technological advancement and high rate of Research & Development initiatives. The growing strategic collaboration is one of the key trends contributing towards the growth of the cystic fibrosis (CF) therapeutics market. The major restraining factors of...
  5. 麻酔薬の世界市場：タイプ別（全身麻酔、脊椎麻酔、末梢神経ブロック、サドルブロック麻酔、斜角筋間ブロック、IV局所麻酔）、投与経路別（注射、吸入）、製品別（プロポフォール、セボフルラン、デスフルラン、レミフェンタニル、ミダゾラム、デクスメデトミジン、その他）、地域別予測
    BZW8D76 / Bizwit Research & Consulting / 2018年11月 / 本資料は、麻酔薬の世界市場について調べ、麻酔薬の世界規模、市場動向、市場環境、タイプ別（全身麻酔、脊椎麻酔、末梢神経ブロック、サドルブロック麻酔、斜角筋間ブロック、IV局所麻酔）分析、投与経路別（注射、吸入）分析、製品別（プロポフォール、セボフルラン、デスフルラン、レミフェンタニル、ミダゾラム、デクスメデトミジン、その他）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。業界の主要なプレイヤーはAstra Zeneca、Abott Laboratories、Baxter International Inc、Boehringer Ingelheim、Eisai Co Ltd、Fresenius SE &...Global Anesthesia Drug Market to reach USD xxx billion by 2025. Global Anesthesia Drug Market valued approximately USD xxx billion in 2017 is anticipated to grow with a healthy growth rate of more than 4.2% over the forecast period 2018-2025. The Anesthesia defined as the temporary condition of unconsciousness, loss of memory, lack of pain and muscle relaxation. In the medical terms the anesthesia has taken its pivotal place in the treatment of diseases and surgeries. In the present scenario, the rising aging population and enhancing medical utility of anesthesia drugs in the medical care and surgeries is anticipated to...
  6. ベータ－ラクタマーゼ阻害薬のパイプライン・インサイト2016
    DIMR2016144 / DelveInsight / 2016年版 / 本調査レポートでは、世界におけるベータ－ラクタマーゼ阻害薬のパイプライン動向について調査・分析し、以下の構成でお届けいたします。 ・ベータ－ラクタマーゼ阻害薬の概要 ・ベータ－ラクタマーゼ阻害薬のパイプライン概要 ・企業別開発中のベータ－ラクタマーゼ阻害薬 ・後期治験段階の薬剤(Filed & Phase III)：比較分析 ・中期治験段階の薬剤(Phase II)：比較分析...SUMMARY DelveInsight’s, “Beta-Lactamase Inhibitors-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Beta-Lactamase Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Beta-Lactamase Inhibitors. DelveInsight’s Report also assesses the Beta-Lactamase Inhibitors...
  7. Beta-Lactamase Inhibitors：阻害薬のグローバル市場2014（薬開発、治験動向）
    DIMR2014144 / DelveInsight / 2014年版 / ...DelveInsight’s,“Beta-Lactamase Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Beta-Lactamase Inhibitors. This report provides information on the therapeutic development based on the Beta-Lactamase Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development...
  8. Beta-Lactamase Inhibitors：阻害薬のグローバル市場2015（薬開発、治験動向）
    DIMRMOA5144 / DelveInsight / 2015年版 / ...DelveInsight’s,“Beta-Lactamase Inhibitors-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Beta-Lactamase Inhibitors. This report provides information on the therapeutic development based on the Beta-Lactamase Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development...
  9. 動脈瘤性くも膜下出血治療薬の世界市場：薬剤クラス別（オピオイド鎮痛薬、カルシウムチャネル遮断薬、抗けいれん薬、便軟化剤、浸透圧性薬剤/利尿剤、その他）
    AMR805015 / Allied Market Research / 2018年4月20日 / 本資料は、動脈瘤性くも膜下出血治療薬の世界市場について調べ、動脈瘤性くも膜下出血治療薬の世界規模、市場動向、市場環境、薬剤クラス別（オピオイド鎮痛薬、カルシウムチャネル遮断薬、抗けいれん薬、便軟化剤、浸透圧性薬剤/利尿剤、その他）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・動脈瘤性くも膜下出血治療薬の世界市場概要 ・動脈瘤性くも膜下出血治療薬の世界市場環境 ・動脈瘤性くも膜下出血治療薬の世界市場動向 ・動脈瘤性くも膜下出血治療薬の世界市場規模 ・動脈瘤性くも膜下出血治療薬の世界市場：薬剤クラス別（オピオイド鎮痛薬、カルシウムチャネル遮断薬、抗けいれん薬、便軟化剤、浸透圧性薬剤/利尿剤、その他） ・動脈瘤性くも膜下出血治療薬の世界市場：地域別市場規模・分析 ・動脈瘤性くも膜下出血治療薬の北米市場規模・予測...Aneurysmal subarachnoid hemorrhage (aSAH) is a condition wherein a brain aneurysm ruptures, resulting in bleeding in the subarachnoid space. In severe cases, bleeding may cause brain damage, leading to paralysis or coma, and even death. The National Institutes of Health (NIH) has stated that aneurysmal subarachnoid hemorrhage (SAH) is a worldwide health burden, with high fatality and permanent disability rates. The global aneurysmal subarachnoid hemorrhage drugs market was valued at $160,269 thousand in 2016, and is estimated to reach $206,675 thousand by 2023, growing at a CAGR of 3.6% from 2017 to 2023. The major factors driving the global aneurysmal...
  10. オピオイドの世界市場：製品別（コデイン、フェンタニル、メタドン、オキシコドン、モルヒネ、ヒドロコドンなど）、用途別（疼痛管理、咳治療、下痢）
    AMR9DC038 / Allied Market Research / 2019年10月 / 当調査レポートでは、オピオイドの世界市場について調査・分析し、イントロダクション、エグゼクティブサマリ－、市場概要、製品別分析、用途別分析、地域別分析、企業概要などを含め以下の構成でお届けします。 ・イントロダクション ・エグゼクティブサマリ－ ・市場概要 ・オピオイドの世界市場：製品別（コデイン、フェンタニル、メタドン、オキシコドン、モルヒネ、ヒドロコドンなど） ・オピオイドの世界市場：用途別（疼痛管理、咳治療、下痢） ・オピオイドの世界市場：地域別 ・企業概要 ...The global opioids market was valued at $18,532.8 million in 2018, and is expected to reach $22,387.2 million by 2026, registering a CAGR of 3.2% from 2019 to 2026. Opioids are drugs that stimulate the brain to produce a variety of effects, including pain relief. The term opioid refers to all substances (exogenous or endogenous) that possess morphine-like properties. Opioids are the most widely prescribed medications to treat moderate to severe chronic pain. These analgesics are used to manage pain in cancer patients and to treat severe constant pain in patients who suffer from terminal illnesses. The growth of the...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆